Products Categories
| CAS No.: | 1812-30-2 |
|---|---|
| Name: | Bromazepam |
| Article Data: | 21 |
| Molecular Structure: | |
|
|
|
| Formula: | C14H10 Br N3 O |
| Molecular Weight: | 316.157 |
| Synonyms: | 2H-1,4-Benzodiazepin-2-one,7-bromo-1,3-dihydro-5-(2-pyridyl)- (7CI,8CI); 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one;7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; Bromazepam;Calmepam; Compendium; Creosedin; Durazanil; KL 001; Lexilium; Lexomil; Lexotan;Lexotanil; Lextonil; NSC 140669; Neoopt; Normoc; Ro 5-3350 |
| EINECS: | 217-322-4 |
| Density: | 1.6g/cm3 |
| Melting Point: | 237-238.5oC (dec.) |
| Boiling Point: | 490.7°Cat760mmHg |
| Flash Point: | 250.6°C |
| Hazard Symbols: |
|
| Risk Codes: | R22;R36/37/38 |
| Safety: | Poison by intraperitoneal route. Moderately toxic by ingestion. An experimental teratogen. Other experimental reproductive effects. Human skin irritant. A tranquilizer. When heated to decomposition it emits very toxic fumes of NOx and HBr. |
| PSA: | 54.35000 |
| LogP: | 2.20720 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 211914-50-0N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
- 240444-70-62,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropancarboxylat
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
Chemistry informtion about Bromazepam (CAS NO.1812-30-2) is:
IUPAC Name: 7-Bromo-5-Pyridin-2-Yl-1,3-Dihydro-1,4-Benzodiazepin-2-One
Synonyms: 7-Bromo-5-[2-Pyridyl]-3h-1,4-Benzodiaxepin-2[1h]-One ; Bromazepam ; 1,3-Dihydro-7-Bromo-5-(2-Pyridyl)-2h-1,4-Benzodiazepin-2-One ; 1,3-Dihydro-7-Bromo-5-(2-Pyridyl)-2h-4-Benzodiazepin-2-One ; 2h-1,4-Benzodiazepin-2-One, 1,3-Dihydro-7-Bromo-5-(2-Pyridyl)- ; 2h-1,4-Benzodiazepin-2-One, 7-Bromo-1,3-Dihydro-5-(2-Pyridinyl)- ; 2h-1,4-Benzodiazepin-2-One, 7-Bromo-1,3-Dihydro-5-(2-Pyridyl)- ; 7-Bromo-1,3-Dihydro-5-(2-Pyridyl)-2h-1,4-Benzdiazepin-2-One
MF: C14H10BrN3O
MW: 316.15
EINECS: 217-322-4
Density: 1.6 g/cm3
Flash Point: 250.6 °C
Boiling Point: 490.7 °C at 760 mmHg
Enthalpy of Vaporization: 75.73 kJ/mol
Vapour Pressure: 8.94E-10 mmHg at 25°C
Storage temp.: 2-8°C
Following is the molecular structure of Bromazepam (CAS NO.1812-30-2) is:
History
Bromazepam is a benzodiazepine derivative drug, developed in the 1970s.
Uses
Bromazepam (CAS NO.1812-30-2) has mainly anxiolytic and at higher doses also sedative, hypnotic and skeletal muscle relaxant properties.
Toxicity Data With Reference
| 1. | skn-hmn 3 mg/3D-I MOD | 85DKA8 Cutaneous Toxicity Drill, V.A. andP. Lazar, eds.,New York, NY.: Academic Press,1977,127. | ||
| 2. | orl-rat LD50:1950 mg/kg | KSRNAM Kiso to Rinsho. Clinical Report. 7 (1973),2413. | ||
| 3. | ipr-rat LD50:1660 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 17 (1979),115. | ||
| 4. | scu-rat LD50:8800 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 17 (1979),115. | ||
| 5. | orl-mus LD50:879 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 17 (1979),115. | ||
| 6. | ipr-mus LD50:200 mg/kg | JDGRAX Journal of Drug Research. 16 (1985),7. | ||
| 7. | scu-mus LD50:6870 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 17 (1979),115. | ||
| 8. | orl-rbt LD50:1690 mg/kg | 27ZQAG Psychotropic Drugs and Related Compounds E. Usdin andD.H. Efron,2nd ed.,Washington, DC.: 1972,158. |
Safety Profile
Poison by intraperitoneal route. Moderately toxic by ingestion. An experimental teratogen. Other experimental reproductive effects. Human skin irritant. A tranquilizer. When heated to decomposition it emits very toxic fumes of NOx and HBr.
Hazard Codes:
Xn
T
F
Risk Statements:
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin.
R39/23/24/25:Danger of very serious irreversible effects and toxic by inhalation, in contact with skin and if swallowed.
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed.
R11:Highly flammable.
Safety Statements:
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36:Wear suitable protective clothing.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36/37:Wear suitable protective clothing and gloves.
S16:Keep away from sources of ignition.
RIDADR: 3249
WGK Germany: 3
RTECS: DE9800000
HazardClass: 6.1(b)
PackingGroup: III
Specification
Bromazepam (CAS NO.1812-30-2) shares with other benzodiazepines the risk of abuse, misuse, psychological dependence and/or physical dependence. A withdrawal study demonstrated both psychological dependence and physical dependence on bromazepam including marked rebound anxiety after 4 weeks chronic use. Those whose dose was gradually reduced experienced no withdrawal. Patients treated with bromazepam for generalised anxiety disorder were found to experience withdrawal symptoms such as a worsening of anxiety, as well as the development of physical withdrawal symptoms when abruptly withdrawn from bromazepam. Abrupt or over rapid withdrawal from bromazepam after chronic use even at therapeutic prescribed doses may lead to a severe withdrawal syndrome including status epilepticus and a condition resembling delerium tremens. It is a Schedule IV drug under the Convention on Psychotropic Substances.